{
    "clinical_study": {
        "@rank": "16533", 
        "arm_group": [
            {
                "arm_group_label": "Bosentan + Exercise", 
                "arm_group_type": "Experimental", 
                "description": "2x/day 62.5 mg Bosentan for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Bosentan for 4 weeks alongside 3x/week supervised exercise"
            }, 
            {
                "arm_group_label": "Placebo + Exercise", 
                "arm_group_type": "Placebo Comparator", 
                "description": "2x/day 62.5 mg Placebo for 4 weeks alongside 3x/week supervised exercise 2x/day 125 mg Placebo for 4 weeks alongside 3x/week supervised exercise"
            }, 
            {
                "arm_group_label": "Exercise", 
                "arm_group_type": "Other", 
                "description": "3x/week supervised exercise for 8 weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to establish the effect of ET blockade on vascular adaptations\n      during an 8-week exercise program in subjects with T2DM. We hypothesize that combining ET -\n      blockade with exercise training leads to an acute increase of exercise induced blood flow\n      when compared with exercise alone. We expect that this will lead to an optimization of\n      vascular training effect in T2DM."
        }, 
        "brief_title": "ET-blockade and Exercise-induced Vascular Adaptations in T2DM", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Type 2 Diabetes Mellitus (>2 years since diagnosis) OR controls\n\n        Exclusion Criteria:\n\n          -  <40 years of age\n\n          -  >65 years of age\n\n          -  smoking\n\n          -  cardiovascular disease\n\n          -  diabetes related manifest vascular complications\n\n          -  Type 1 Diabetes Mellitus\n\n          -  use of Glibenclamide\n\n          -  use of HIV drugs\n\n          -  use of calcineurin inhibitors\n\n          -  use of drugs that interfere with CYP3A4 and CYP2C19"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "36", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 28, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01779609", 
            "org_study_id": "ET-EX-TRAINING"
        }, 
        "intervention": [
            {
                "arm_group_label": "Bosentan + Exercise", 
                "intervention_name": "Bosentan", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Bosentan", 
                    "Tracleer", 
                    "actelion pharmaceuticals"
                ]
            }, 
            {
                "arm_group_label": "Placebo + Exercise", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Placebo", 
                    "actelion pharmaceuticals"
                ]
            }, 
            {
                "arm_group_label": [
                    "Bosentan + Exercise", 
                    "Placebo + Exercise", 
                    "Exercise"
                ], 
                "description": "Supervised exercise training program of 8 weeks, for 3x/week", 
                "intervention_name": "Exercise", 
                "intervention_type": "Behavioral", 
                "other_name": "Supervised Exercise Training Program"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Bosentan"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "January 28, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Nijmegen", 
                    "country": "Netherlands", 
                    "state": "Gelderland", 
                    "zip": "6525 EX"
                }, 
                "name": "Radboud University Nijmegen Medical Centre"
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "3", 
        "official_title": "Effect of a Dual ET(Endothelin)-Blocker on Exercise Induced Vascular Adaptations in Type 2 Diabetes Mellitus (T2DM)", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Flow mediated dilation", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01779609"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Conduit Artery Dilator Capacity", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Intima-Media Thickness", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "Maximal Oxygen Uptake", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }
        ], 
        "source": "Radboud University", 
        "sponsors": {
            "collaborator": {
                "agency": "Actelion", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Radboud University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care", 
        "study_type": "Interventional", 
        "verification_date": "February 2010"
    }
}